Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

RECRUITING

NCT06508775

NA

Sponsor: Miltenyi Biomedicine GmbH

View on ClinicalTrials.gov

Summary

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-05-05

Completion Date

2040-12-31

Last Updated

2025-11-26

Healthy Volunteers

No

Conditions

Melanoma Stage III B-cell Non Hodgkin Lymphoma Pediatric ALL Childhood Non-Hodgkin Lymphoma Acute Lymphatic Leukemia Chronic Lymphatic Leukemia Melanoma Stage IV

Interventions

BIOLOGICAL

MB-CART19.1

Assessment of long-term safety and efficacy of MB-CART19.1 treatment.

BIOLOGICAL

MB-CART20.1

Assessment of long-term safety and efficacy of MB-CART20.1 treatment.

BIOLOGICAL

MB-CART2019.1

Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.

Locations (7)

Charité Universitätsmedizin Berlin

Berlin, Germany

Universitätsklinikum Köln

Cologne, Germany

Uniklinikum Erlangen

Erlangen, Germany

Universitätsmedizin Göttingen

Göttingen, Germany

Universitätsklinikum Münster

Münster, Germany

Universitätsklinikum Tübingen

Tübingen, Germany

Universitäts-Kinderklinik Würzburg

Würzburg, Germany

Clinical Research Directory